Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.62 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11545126 | 0.98 | CES2 (0.60) | CES2SRD5A2LMNAGAAMAOB | |
| SCHEMBL3543279 | 0.84 | SRD5A2 (0.45) | CES2SRD5A2LMNAGAAMAOB | |
| SCHEMBL10672352 | 0.83 | CES2 (0.62) | CES2SRD5A2LMNAGAANPSR1 | |
| SCHEMBL10842400 | 0.83 | CES2 (0.67) | CES2SRD5A2LMNAMAOBKCNK3 | |
| SCHEMBL1449175 | 0.82 | CES2 (0.60) | CES2SRD5A2LMNAGAANPSR1 | |
| SCHEMBL1198420 | 0.82 | CES2 (0.60) | CES2SRD5A2GAA | |
| SCHEMBL4086253 | 0.80 | CES2 (0.69) | CES2SRD5A2LMNAMAOBKCNK3 | |
| SCHEMBL29433907 | 0.79 | SRD5A2 (0.77) | CES2SRD5A2LMNAMAOBKCNK3 | |
| SCHEMBL40186 | 0.79 | SRD5A2 (0.77) | CES2SRD5A2LMNAMAOBKCNK3 | |
| SCHEMBL17894211 | 0.79 | CES2 (0.62) | CES2SRD5A2LMNAGAAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012075242-A2 | CONTROLLED CHEMICAL RELEASE OF HYDROGEN SULFIDE | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | WO | disclosed |
| CN-1805748-B | 2-aminopyrimidine derivatives as RAF kinase inhibitors | NOVARTIS AG | 2010-05-26 | — | — | CN | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| CN-1805748-A | 2-aminopyrimidine derivatives as RAF kinase inhibitors | NOVARTIS AG (CH) | 2006-07-19 | — | — | CN | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-0167919-B1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| US-5204482-A | Ethylenediamine monoamide heteroaryl derivatives | HOFFMAN-LAROCHE INC. (US) | 1993-04-20 | — | — | US | disclosed |
| US-5011849-A | Monoamine oxidase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1991-04-30 | — | — | US | disclosed |
| US-5004741-A | Cholecystokinin(CCK); Treating Disorders Of The Gastrointestinal Tract, Central Nervous System And Of The Appetite Of Animals | MERCK & CO., INC. (US) | 1991-04-02 | — | — | US | disclosed |
| US-4820834-A | Benzodiazepine analogs | MERCK & CO., INC. (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0284256-A1 | Benzodiazepine analogs | MERCK & CO. INC. (US) | 1988-09-28 | — | — | EP | disclosed |
| EP-0167919-A2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-01-15 | — | — | EP | disclosed |
| US-4296092-A | Mucolytic benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts | A. H. ROBINS COMPANY, INC. (US) | 1981-10-20 | — | — | US | disclosed |
| US-4198428-A | PESTICIDES, MICROBIOCIDES, MOLLUSCOCIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | CES2 625/4885SRD5A2 2467/4885LMNA 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.